Skip to content
Events

Details

Hear about the experiences from one of our early access sites who tested the novel Illumina Complete Long Reads assay which enables an easy and scalable workflow.

The Wellcome Sanger Institute evaluated Illumina’s innovative long-read sequencing technology; Illumina Complete Long Reads.  Listen to seasoned NGS and long-read expert, Dr Michael Quail as he shares his first-hand experience with this transformative technology. 

Register to watch the on-demand webinar

Your email address is never shared with third parties.

Date & Time
11 Jul 2023
Location
Europe
Affiliation
Principal Scientific Manager, Wellcome Sanger Institute, UK
Presenter
Dr. Michael Quail
Watch Now
M-EMEA-01043
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.